BCAT1 Antibody (Center) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P54687 |
---|---|
Other Accession | NP_001171563.1, NP_001171562.1, NP_005495.2, NP_001171564.1, NP_001171565.1 |
Clone Names | 90723018 |
Gene ID | 586 |
---|---|
Other Names | Branched-chain-amino-acid aminotransferase, cytosolic, BCAT(c), Protein ECA39, BCAT1, BCT1, ECA39 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | BCAT1 |
---|---|
Synonyms | BCT1, ECA39 |
Function | Catalyzes the first reaction in the catabolism of the essential branched chain amino acids leucine, isoleucine, and valine. |
Cellular Location | Cytoplasm. |
Tissue Location | During embryogenesis, expressed in the brain and kidney. Overexpressed in MYC-induced tumors such as Burkitt's lymphoma |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes the cytosolic form of the enzymebranched-chain amino acid transaminase. This enzyme catalyzes thereversible transamination of branched-chain alpha-keto acids tobranched-chain L-amino acids essential for cell growth. Twodifferent clinical disorders have been attributed to a defect ofbranched-chain amino acid transamination: hypervalinemia andhyperleucine-isoleucinemia. As there is also a gene encoding amitochondrial form of this enzyme, mutations in either gene maycontribute to these disorders. Alternatively spliced transcriptvariants have been described.
References
Eijgelsheim, M., et al. Hum. Mol. Genet. 19(19):3885-3894(2010)Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :Barber, M.J., et al. PLoS ONE 5 (3), E9763 (2010) :Talmud, P.J., et al. Am. J. Hum. Genet. 85(5):628-642(2009)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.